Completion of Successful Series B Equity Financing

LaZure Scientific recently announced the successful close of its Series B preferred Equity Financing. Total proceeds from the round were not disclosed, however, LaZure CEO Charles Hill noted “Funds from our Successful Series B Round will allow us to continue our preclinical testing to validate the safety and effectiveness of our technology and continue making progress towards the ultimate goal of gaining regulatory clearance to market the LDAEC therapy system.”
The LaZure Low Dose Alternating Electric Current (LDAEC) technology is an electrosurgical instrument system that delivers a low-intensity, intermediate frequency alternating electric field to a desired target tissue area, such as the prostate, to preferentially destroy cancerous tissue and lesions while limiting treatment related side effects by sparing vital tissue types including smooth muscle, nerves, and large blood vessels. Observations from non-clinical studies suggest that LDAEC may hold promise as novel therapy for certain cancer types.

Sorry, comments are closed for this post.